Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Scientists from the Research Institute of Internal Medicine receive funding from ERA-Net

 
From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen
From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen

Professor Pål Aukrust has together with senior scientist dr. Arne Yndestad and professor Bente Halvorsen received ERA-NET funding on cardiovascular diseases (ERA-CVD). All three scientists are affiliated Research Institute of Internal Medicine at the Division of Surgery, Inflammatory Medicine and Transplantation (“KIT”), Oslo University Hospital and Institute of Clinical Medicine, University of Oslo.

The funding, amounting to 2.4 mill NOK over a period of three years, is based on a collaborative project with professor Joachim Schultze, Bonn, Germany, professor Michael Sieweki, Marseille, France, and professor Erik A Biessen, Maastricht, The Netherlands, who is heading the consortium. The project named AtheroMacHete (Atherosclerosis Macrophage Heterogeneity study) will particular focus on intra plaque macrophage heterogeneity in patients with atherosclerotic disorders and experimental model systems.

 
 

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2017

 
Award winners during the ceremony (photo Pål Bakke)
Award winners during the ceremony (photo Pål Bakke)

Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

 
 

Per Steinar Halvorsen appointed "Innovator of the Month" by Helse Sør-Øst

 
Per S.Halvorsen(photo: Hedda Holth)
Per S.Halvorsen
(photo: Hedda Holth)

Per Steinar Halvorsen, head of the "Clinical and experimental cardiovascular monitoring" research group at the Intervention Centre at the Division of Emergencies and Clinical Care, was appointed "Innovator of the Month" for the month of October by South-Eastern Norway Regional Health Authority (Helse Sør-Øst).
His work is presented in an article (in Norwegian) entitled "Pacemaker of the future", published on the home page of Helse Sør-Øst.

 
 

Press release – 29 Nov 2017

The Laboratory of Adaptive Immunity and Homeostasis enters a strategic research collaboration with a leading pharmaceutical company

 
Jan T. Andersen (photo: UiO/Ø.H. Horgmo)
Jan T. Andersen (photo: UiO/Ø.H. Horgmo)

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is combining structural and biophysical approaches with cellular and animal studies to unravel how the neonatal Fc receptor (FcRn) acts as a key player in regulation of the long serum half-life of albumin and IgG antibodies. The research group has signed a strategic research agreement with Roche Diagnostics GmbH where the aim will be to gain an in-depth understanding on how FcRn is regulating transport of engineered IgG antibodies in different types of cells. The agreement is part of the Roche Postdoctoral Fellowship program.

 
 

Alicia Llorente participates in an ERA-NET funded project

 
Alicie Llorente
Alicie Llorente

Alicia Llorente, project group leader at the Department of Molecular Cell Biology in the research group headed by Kirsten Sandvig, has recently received a grant to participate in a project funded by the Horizon2020 action ERA-NET TRANSCAN-2. TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils that aims to align national/regional translational cancer research programmes.
Both The Norwegian Research Council and The Norwegian Cancer Society participate in TRANSCAN-2. The project is funded by the Third Joint Transnational Call (JTC 2016) dedicated to "Minimally and non-invasive methods for early detection and/or progression of cancer". A total of 14 projects were funded under this call, and three of them have Norwegian participants.

 
 

Update: Nature Cell Biology paper draws attention:

Rusten group uncovers new regulatory mechanism of the Peutz-Jeghers cancer syndrome kinase, LKB1

 
Team at Centre for Cancer Biomedicine behind the study
Team at Centre for Cancer Biomedicine behind the study

Structural breakdown of epithelial architecture is a cardinal hallmark of carcinomas - the most common forms of cancer.
Our cells contain tumor suppressor genes that act as gate-keepers to prevent tumor growth. One such classical tumor suppressor, Liver Kinase B1 (LKB1), was identified as being responsible for the hereditary cancer predisposition syndrome, Peutz-Jeghers syndrome. It has later been shown to be mutated in other cancer types, such as lung cancer.
Reporting in the prestigeous journal Nature Cell Biology (IF 20,6), O´Farrell and colleagues now reports that intracellular endocytic trafficking of LKB1 is essential to curtail Lkb1 activity from going rogue. In a surprising twist, they show that LKB1 can act to promote carcinogenesis, a role normally possessed by oncogenes.

Update: PNAS has published a commentary article about the findings in their "Journal Club" section, where recently published papers selected by Academy members are highlighted. 

 
 

Young Investigator Prize to Anita Sveen during annual "Onkologisk Forum" meeting Nov 2017

 
Anita Sveen
Anita Sveen

Dr. Anita Sveen from Ragnhild Lothe's group at the Department of Molecular Oncology received the Young Investigator prize at Onkologisk Forum for her research accomplishments. This annual meeting for oncologists took place in Oslo on November 16-17. The award amounts to 50.000 NOK, to be spent on research.

Sveen presented her research in computational oncology, focusing on clinical relevant questions for colorectal cancer and novel results published in 6 selected papers.

 
 

Michael Bretthauer appointed "Scientist of the Month" by "Helse Sør-Øst"

 
M. Bretthauer
M. Bretthauer

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".

For the month of October 2017, this honour went to Michael Bretthauer from the Department of Transplantation Medicine at the Division of Surgery, Inflammatory Diseases and Transplantation.

 
 

Paper on novel pathway selected for inclusion in the ‘In This Issue’ section of Journal of Cell Science

 
Beata Grallert (left) and Christiane Rothe
Beata Grallert (left) and Christiane Rothe

Cell-cycle checkpoints are crucial for the maintenance of genomic integrity. The checkpoint operating in G2 phase of the cell cycle prevents entry into mitosis in the face of DNA damage. In cancer cells checkpoints are often deficient and thus they most likely rely on alternative pathways.
The authors describe a novel pathway for delayed entry into mitosis in response to DNA damage, which does not depend on the classic checkpoint pathways. Instead, the pathway involves selective translation regulation of a key mitotic regulator, cyclin B. This work is the first demonstration of selective translation regulation of a cell-cycle regulator in response to DNA-damage stress and raises the question whether similar pathways also exist in cancer cells with impaired checkpoints.
The findings are selected for the "In this issue" section in "Journal of Cell Science" on Dec 1st.

 
 

Jan Terje Andersen receives a grant of 8.5 million NOK from NANO2021

 
Jan Terje Andersen
Jan Terje Andersen

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. By combining structural and biophysical approaches with cellular and in vivo studies, they use the insights to design novel albumin and antibody molecules with improved functions. The research group has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to expand their work on how such engineered ligands can be explored in combination with nanoparticles for tailored mucosal delivery. The project is entitled “A novel nanoparticle-based approach for mucosal delivery of therapeutics".
There were 61 applicants, of which two (including this application) obtained the highest possible rate.